Could a cheap blood thinner cut stroke risk in africa?

NCT ID NCT06919835

Not yet recruiting Prevention Sponsor: Northern California Institute of Research and Education Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether the drug cilostazol can prevent recurrent strokes and heart problems in 1100 recent stroke survivors in Ghana. Participants take either cilostazol or a placebo twice daily for 24 months. The goal is to see if this affordable drug, already used in Asia, can reduce major cardiovascular events in a high-risk African population.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cilostazol (a blood-thinning drug that helps prevent blood clots)
What this could lead to: If it works, this could provide an affordable and effective way to prevent recurrent strokes in low-resource settings like sub-Saharan Africa.
What could go wrong: This trial is still recruiting and results are not yet available. Previous promising data came mainly from Asian populations, so it may not work as well in Africans. Side effects like bleeding are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH-RISK TRANSIENT ISCHEMIC ATTACK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke transient ischemic attack stroke disorder prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

STROKE

Contacts and locations

Locations

Kwame Nkrumah University of Science & Technology

Kumasi, Ghana

More trials for these conditions

Other studies related to the condition(s) this trial covers.